August 31 – September 3 | Riyadh
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend LEAP 2026 on September 2. He will deliver a presentation at the "Deep Dive: Rewriting Healthcare with Predictive Intelligence" forum at 15:10, followed by a panel discussion titled "Beyond the Horizon: Breakthroughs at the Edge of Market Entry" at 18:05. As a pioneer in AI drug discovery and health technology, Dr. Zhavoronkov will elaborate on how Insilico Medicine leverages artificial intelligence to disrupt traditional healthcare paradigms, shifting drug discovery from reactive treatment to intelligent prevention and precision intervention. Additionally, he will share insights into how Insilico navigates the high-regulation and fiercely competitive landscape at the threshold between technical breakthroughs and market entry, accelerating the commercialization and deployment of its disruptive pipeline.
About LEAP 2026 As a world-renowned technology event held in Riyadh, Saudi Arabia, LEAP 2026 aligns with Saudi Vision 2030, centering on digital futures and disruptive innovation. The event gathers global tech leaders, investment giants, and innovation pioneers. It focuses on the commercialization of cutting-edge technologies—such as generative AI, AI-driven drug discovery (AIDD), and computing infrastructure—showcasing breakthrough achievements at the edge of market entry. Serving as a global tech ecosystem hub, LEAP offers an efficient platform for cross-border capital matching and industrial cooperation.
September 1 | Shenzhen
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, will attend the UBS China A-Share Conference 2026 in Shenzhen on September 1, participating in a panel discussion and delivering a speech. As a leader in AI drug discovery and frontier technology, Dr. Ren will detail how Insilico Medicine uses AI to reshape R&D paradigms, enhancing efficiency and innovation value. Drawing on the company’s latest pipeline progress and strategic layout, he will also share strategies for commercializing AI-driven breakthrough therapies in the current market environment while collaborating with capital and industry partners to explore long-term investment value.
About the UBS China A-Share Conference
The UBS China A-Share Conference is a flagship capital markets event organized by UBS Group, dedicated to building an authoritative bridge between top global institutional investors and leading domestic listed companies. Bringing together sovereign wealth funds, asset management giants, and executives from hundreds of A-share companies, the conference addresses macroeconomics, hard-tech breakthroughs, and corporate global expansion. Through keynote speeches and one-on-one sessions, it offers insights into investment trends, connecting global capital with China’s innovation dividend.
September 2 | Suzhou
Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 6th SCS Healthcare Conference in Suzhou on September 2 to deliver a keynote speech. As a leader in AI drug discovery, he will articulate how AI drives paradigm shifts in drug discovery, accelerating the transition from target identification to preclinical candidate nomination. He will also discuss leveraging core technologies to break R&D bottlenecks, enhance pipeline commercial value, and explore future opportunities with industry and capital market partners.
About the SCS Healthcare Conference
The SCS Healthcare Conference is a premier healthcare event hosted by Soochow Securities. Grounded in China’s biopharmaceutical innovation and aligned with national innovation strategies, the summit builds an integrated ecosystem connecting industry, capital, and academia. Gathering business development (BD) heads from global pharma, executives from innovative biotech firms, scientific experts, and major investment institutions, the conference focuses on core topics such as tech breakthroughs, global commercialization, cross-border BD deals, and diversified payment mechanisms. Through keynote speeches, panel discussions, and roadshows, it serves as an industry bellwether driving the translation of innovative results and empowering high-quality biopharmaceutical development.
September 6 | Xiamen
Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 2026 Xiamen Tech Innovation and Securities Industry Development Conference on September 6, delivering a keynote speech titled "From Technological Breakthrough to Clinical Validation: The Second Half of AI Pharma." He will share how Insilico Medicine pushes AI drug discovery from technical validation into clinical translation, detailing how advanced algorithms boost clinical success rates and accelerate commercial value creation for complex disease pipelines.
About the 2026 Xiamen Tech Innovation and Securities Industry Development Conference
Themed "New Quality Leadership, Capital Empowerment, Wisely Igniting the Future," the conference aligns with Xiamen’s "4+4+6" modern industrial framework. It convenes top-tier tech enterprises, securities firms, and investment giants to build a high-quality industry-finance matching platform. The event addresses capital market reforms, exploring how the securities industry can support tech enterprises across their lifecycle and how hard-tech firms can achieve leapfrog growth via capital markets. Through keynote speeches, panel discussions, and project roadshows, the conference fosters synergies between tech resources and financial forces to build a thriving regional innovation ecosystem.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, HKEX:3696.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.